Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-AF: Optimal antiplatelet therapy with DOACs after PCI in atrial fibrillation
jRCTs051190053Completed
- Sponsor
- Abbott Laboratories
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Draxaban, clopidogrel, prasugrel and aspirin in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Efficacy primary endpoint and Safety primary endpoint. Started Oct 2019; status: completed.
02
Drugs
Draxabanclopidogrelprasugrelaspirin
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCTs051190053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190053.